No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study.

@article{Rinaldi2010NoEO,
  title={No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study.},
  author={Luciano Rinaldi and Francesca Rinaldi and Paola Perini and Massimiliano Calabrese and Dario Seppi and Paola Grossi and Irene Mattisi and Luisa Barzon and Carlo Mengoli and Mariella Sanzari and Giorgio Pal{\`u} and Paolo Gallo},
  journal={Journal of neurology, neurosurgery, and psychiatry},
  year={2010},
  volume={81 12},
  pages={
          1345-50
        }
}
BACKGROUND AND AIM Natalizumab, used as therapy for multiple sclerosis (MS), has been associated with progressive multifocal leucoencephalopathy (PML), a potentially fatal disease caused by JC virus (JCV), which is not predictable by specific markers. This study evaluated whether JCV reactivation occurred in the urine and/or plasma in 42 MS patients treated with natalizumab over 18 months, and followed by a thorough monitoring programme. METHODS 42 patients (F/M: 24/18, mean age 34.4±8.9… CONTINUE READING
BETA
Highly Cited
This paper has 38 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
SHOWING 1-10 OF 18 CITATIONS

Similar Papers

Loading similar papers…